Current Management of Retinal Vein Occlusion Robert A. Mittra, MD VRS Course 2015
|
|
- Peregrine Matthews
- 7 years ago
- Views:
Transcription
1 Central Retinal Vein Occlusion Hemi-Central Vein Occlusion Current Management of Retinal Vein Occlusion Robert A. Mittra, MD VRS Course 2015 Branch Retinal Vein Occlusion Ischemic vs. non-ischemic BRVO BRVO 1
2 Systemic risk factors Newman-Casey Ophthalmol 2014 Survey of Medicare database Hypertension Diabetes Natural History Decroos AJO 2011 has discussed the difficulty of using randomized trials for natural history Control groups were small or had different entrance criteria or lumped together different groups of diseases Hayreh JAMAOpthalmol 2014 BRVO Divided into major and macular Resolution of edema in months Overall outcome is good Median final VA 20/60 for both types Natural History Hayreh Ophthalmol 2011 Non-ischemic is 20/100 in 83% Hayreh Retina 2012 HRVO Improves 50% of the time without therapy Unmet Need in Retinal Vein Occlusion 2 nd leading cause of blindness for patients with retinal vascular disease RVO Incidence 180,000 eyes/yr U.S. 80% BRVO 20% 70% Non- Ischemic 30% Ischemic DEMOGRAPHICS Mean age at onset: 65 yrs Male:Female ratio: 1.2:1 Risk Factors: Open-angle glaucoma, HTN, DM, and arteriosclerosis Outcome predictors: VA at diagnosis and age Long-term VA Outcomes 3 Yrs BRVO 1 2 > 20/40 34% 12% 20/50-20/200 43% 62% < 20/200 23% 26% 1 BVOS: AJO 98: , CVOS: Ophthalmology 102: , , Genentech / Proprietary information Please do not copy, distribute or use without prior written consent. Treatment options Observation Laser Focal for macular edema PRP for ischemia and NVI Anti-VEGF therapy Bevicizumab (Avastin) Ranibizumab (Lucentis) Aflibercept (Eylea) Steroid Intravitreal triamcinolone (Triesence) Dexamethasone implant (Ozurdex) Observation May still be an option for mild BVO and without significant visual loss from macular edema Extramacular BVO almost universally is observed Ischemic BRVO without leakage on FA may improve without therapy 2
3 30% Spontaneous Recovery BRVO 3 Month Observation 70% Disease Progression 3 Macular Grid Laser BRVO: Laser v. Observation 1 Laser Observation > 2 line VA 1 Yr* ~20% ~7% Mean 1 Yr n/a n/a Observation Only <25% Guarded d >75% Disease Recovery Progression : Observation 2 Observation > 3 line VA 1 Yr* 6% Mean 1 Yr - 3 letters Laser BVOS study showed that macular laser is better than observation Tan AJO 2014 showed that intravitreal Lucentis gives superior visual results when compared to Laser Campochiaro Ophthalmol 2014 showed intravitreal Eylea better than grid laser at 6 months (VIBRANT) Shah et al feel that focal/grid laser may still be useful in cases of BRVO Pichi Ophthalmol 2014 showed that Ozurdex and grid laser are synergistic for improvement in vision and decreasing frequency of injections Farese Eur J Ophthalmol 2014 showed grid laser with Avastin effective for treatment of BRVO Mean 3 Yrs letters + 1 letter Mean 3 Yrs - 3 letters 2009, Genentech 1 BVOS: / Proprietary AJO 98: information , 1984 Please 2 CVOS: do not copy, Ophthalmology distribute or 102: use without , prior Arch Ophthalmology; 110: , 1992 written consent. Laser CVOS study showed grid laser in not beneficial for treatment of macular edema Shah AJO 2011 feel that there may still be a role for laser for treatment of areas of capillary dropout Area of non-perfusion in often increases over time even with therapy (prn therapy with anti-vegf and dexamethasone implant) Retinal Vein Occlusion Pathophysiology Retinal vein compression and narrowing Turbulent blood flow Thrombus formation Ischemia and hypoxia Increased VEGF production Increased capillary permeability (Branch) BRVO (Central) Christoffersen NL, Larsen M. Ophthalmology :2054. Fegan CD. Eye :98. Noma H, et al. Graefes Arch Clin Exp Ophthalmol : , Genentech / Proprietary information Please do not copy, distribute or use without prior written consent. Leakage and edema Vision Loss Anti-VEGF Therapy Marked effect on macular edema, can be see within 1 hour of treatment (Ma Can J Ophthalmol 2014) Avastin Epstein, Algvere Ophthalmol 2012 Effective for over 2 years if therapy is continued every 6 weeks Greater than 15 letter increase in vision in 60% Lucentis Varma Ophthalmol 2012 BRAVO and CRUISE trials showed significant visual gain with Lucentis monthly for 6 months Campochiaro/Wycoff Ophthalmol 2014 showed that after 7 monthly treatments can go prn with Lucentis (SHORE) Anti-VEGF therapy Eylea Brown AJO 2013 showed monthly dosing for 6 months and then prn to 1 year is effective Korobelnik Ophthalmol 2014 showed similar for 1 year for (GALILEO) Ogura AJO 2014 showed similar results for 1.5 years 3
4 Steroid Scott Arch Ophthalmol 2012 SCORE BVO showed no difference between laser and IOS at 1 year SCORE showed vision was better at 1 year with IOS, but only a small percentage benefit (27%) Haller Ophthalmol 2011 Ozurdex effective for BRVO and in reducing macular edema and improving vision Shaikh Ophth Surg/Laser 2013 showed Ozurdex as effective in vitrectomized eyes as those without Timing of treatment Thach Ophthalmol 2014 showed early treatment with Lucentis much better for BRVO/ with monthly rx for 6 months, rescue treatment not as good Ogura AJO 2014 showed a similar result with Eylea for, rescue treatment not effective Ideally want to see and initiate treatment on patients within the first 1-2 months after onset Long term Therapy? Kinge AJO 2010 showed long term therapy is required to maintain vision gains in patients treated with Lucentis Heier Ophthalmol 2014 (COPERNICUS) 2 year follow-up of Eylea for showed the visual gains noted at 1 year were lost with less frequent follow up in year 2 Once disease recurs may not do as well,?long term treatment every 2 months Heier/Campochiaro Ophthalmology 2012 (HORIZON) decrease in Follow-up in year 2 resulted in loss of vision for, but not BRVO patients treated with Lucentis Non-perfusion Sadda Ophthalmol 2013 showed Ozurdex treated patients have stabilization of NV and macular edema but non-perfusion increases despite therapy Sophie Ophthalmol 2013 showed prn treatment with Lucentis allows for an increase in retinal non-perfusion and loss of visual gains achieved 4
5 Campochiaro/Sophie Ophthalmol 2014 (RETAIN) 4 year follow-up of Lucentis for BRVO/ Most BRVO did well long term with resolution of fluid by 2 years Of those still requiring injections, 80% were >20/40 44% of had resolution of edema within 4 years, but the majority still needed injections beyond with a guarded prognosis for vision Data do not apply to those with Va <20/400 or and APD Poor outcomes seen in patients with increased age, HTN and ischemia Hahn AJO 2013 Eylea, Lucentis, Avastin, Ozurdex are all shown to be effective for BRVO/ compared to sham injections Unknown how they are against each other Unknown how they should be used long term More unknown than known Take Home Message What to tell patients? BRVO Prognosis is good for retained or improved vision Will need therapy for at least 2 years May consist of injections of various agents and laser (non-ischemic) Prognosis is guarded for long term vision About a 4/10 chance of improvement Therapy beyond 2 years is likely May consist of injections of various agents and possibly laser 5
6 Thank You 6
An Informational Guide to CENTRAL RETINAL VEIN OCCLUSION
Science of CRVO www.scienceofcrvo.org An Informational Guide to CENTRAL RETINAL VEIN OCCLUSION This brochure will guide you in understanding CRVO and the treatment options available to prevent vision loss.
More informationAvastin (Bevacizumab) Intravitreal Injection
Avastin (Bevacizumab) Intravitreal Injection This handout describes how Avastin may be used to treat wet age related macular degeneration (AMD) or macular edema due to retinal vascular disease such as
More informationFDA approves Lucentis (ranibizumab injection) for treatment of diabetic macular edema
Media Release Basel, 13 August 2012 FDA approves Lucentis (ranibizumab injection) for treatment of diabetic macular edema First major treatment advance in more than 25 years for sight-threatening condition
More informationDexamethasone intravitreal implant for the treatment of macular oedema secondary to retinal vein occlusion
Dexamethasone intravitreal implant for the treatment of macular oedema secondary to retinal vein occlusion Issued: July 2011 guidance.nice.org.uk/ta229 NICE has accredited the process used by the Centre
More informationIR Conference Call on EYLEA (aflibercept) Injection in Diabetic Macular Edema. September 28, 2013
IR Conference Call on EYLEA (aflibercept) Injection in Diabetic Macular Edema September 28, 2013 Safe Harbor Statement This presentation includes forward-looking statements that involve risks and uncertainties
More informationACTVE INTERVENTIONAL CLINICAL TRIALS - 03/01/2015. Principal Investigator Study Title and Sponsor Study Description
Cornea and External Disease Service Li, Jennifer A Prospective, Multicenter Post-Approval Study (PAS) of VisionCare s Implantable Miniature Telescope (by Dr. Isaac Lipshitz) in Patients with Bilateral
More informationAge- Related Macular Degeneration
Age- Related Macular Degeneration Age-Related Macular Degeneration (AMD) is the leading cause of blindness in the United States. It is caused by damage to a localized area of the central retina called
More informationPeptide and Sustained Release Technology to Treat Ocular Diseases and Cancer
Peptide and Sustained Release Technology to Treat Ocular Diseases and Cancer Jordan Green, PhD, Co-Founder and CEO Wendy Perrow, MBA, Senior Business Advisor February 11, 2015 www.asclepix.com Advantages
More informationOhr Pharmaceutical Reports Fiscal Year 2015 Financial and Business Results
December 10, 2015 Ohr Pharmaceutical Reports Fiscal Year 2015 Financial and Business Results OHR-102 Phase 3 Program in Wet-AMD to be Initiated Upon Completion of SPA; Enroll Patients in Q1 2016 Conference
More informationCompleted Clinical Research Trials Prema Abraham, M.D.
Completed Clinical Research Trials Prema Abraham, M.D. AMD Studies 2010 Present Principal Investigator: A Phase 2, randomized, double-masked, controlled trial to establish the safety and efficacy of intravitreous
More informationVisual Disorders in Middle-Age and Elderly Patients with Diabetic Retinopathy
Medical Care for the Elderly Visual Disorders in Middle-Age and Elderly Patients with Diabetic Retinopathy JMAJ 46(1): 27 32, 2003 Shigehiko KITANO Professor, Department of Ophthalmology, Diabetes Center,
More informationINTERNATIONAL CLINICAL DIABETIC RETINOPATHY DISEASE SEVERITY SCALE DETAILED TABLE
Proposed Disease Severity Level No apparent Mild Non- Proliferative Moderate Nonproliferative Severe Non- Proliferative Proliferative INTERNATIONAL CLINICAL DIABETIC RETINOPATHY DISEASE SEVERITY SCALE
More informationIntroduction. Stephan Michels, MD, MBA, is a professor at the University of Zurich and vice chair at Triemli Hospital in Zurich, Switzerland.
Introduction A panel of experts gathered during the 2015 annual meeting of the American Academy of Ophthalmology to participate in a roundtable discussion regarding protocols for the treatment of diabetic
More information12-month results of the standardised combination therapy for diabetic macular oedema: intravitreal bevacizumab and navigated retinal photocoagulation
BJO Online First, published on April 10, 2014 as 10.1136/bjophthalmol-2013-304488 Clinical science 12-month results of the standardised combination therapy for diabetic macular oedema: intravitreal bevacizumab
More informationBRANCH RETINAL VEIN OCCLUSION (BRVO) AND LASER TREATMENT
INTRODUCTION: BRANCH RETINAL VEIN OCCLUSION (BRVO) AND LASER TREATMENT Branch Retinal Vein Occlusion (BRVO) involves the obstruction of a major venous blood vessel which prevents adequate drainage of blood
More informationNAVILAS Laser System Focal Laser Treatment for Diabetic Macular Edema - One Year Results of a Case Series
Send Orders for Reprints to reprints@benthamscience.net 48 The Open Ophthalmology Journal, 2013, 7, 48-53 Open Access NAVILAS Laser System Focal Laser Treatment for Diabetic Macular Edema - One Year Results
More informationCorporate Medical Policy
Corporate Medical Policy Intravitreal Implant File Name: Origination: Last CAP Review: Next CAP Review: Last Review: intravitreal_implant 11/2010 6/2015 6/2016 6/2015 Description of Procedure or Service
More informationAlexandria Fairfax Sterling Leesburg 703-931-9100 703-573-8080 703-430-4400 703-858-3170
DIABETIC RETINOPATHY www.theeyecenter.com This pamphlet has been written to help people with diabetic retinopathy and their families and friends better understand the disease. It describes the cause, symptoms,
More informationRanibizumab for Macular Edema following Central Retinal Vein Occlusion
for Macular Edema following Central Retinal Vein Occlusion Six-Month Primary End Point Results of a Phase III Study David M. Brown, MD, FACS, 1 Peter A. Campochiaro, MD, 2 Rishi P. Singh, MD, 3 Zhengrong
More informationDiabetes & blindness. due to DME BLINDNESS IN EUROPE
Diabetes & blindness due to DME BLINDNESS IN EUROPE Blindness is a life-changing disability which puts a heavy strain on the daily lives of sufferers, their families, and society at large. Today, 284 million
More informationDIABETIC RETINOPATHY. Diabetes mellitus is an abnormality of the blood glucose metabolism due to altered
DIABETIC RETINOPATHY Diabetes mellitus Diabetes mellitus is an abnormality of the blood glucose metabolism due to altered insulin production or activity. There are two types diabetes mellitus- Insulin
More informationAffiliation : ASSOCIATION FOR RESEARCH IN VISION AND OPHTHALMOLOGY (ARVO). AMERICAN ACADEMY OF OPHTHALMOLOGY (AAO)
Curriculum Vitae Federico Ricci, MD Name: Federico Ricci, MD. Titolo Accademico /Title: Professore Aggregato di Oftalmologia / Aggregate Professor of Ophthalmology Direttore UOSD Patologie Retiniche [Centro
More informationNC DIVISION OF SERVICES FOR THE BLIND POLICIES AND PROCEDURES VOCATIONAL REHABILITATION
NC DIVISION OF SERVICES FOR THE BLIND POLICIES AND PROCEDURES VOCATIONAL REHABILITATION Section: E Revision History Revised 01/97; 05/03; 02/08; 04/08; 03/09; 05/09; 12/09; 01/11; 12/14 An individual is
More informationAPRIL 8th 2016 Therapy
APRIL 8th 2016 Therapy 09.00-10.00 SESSION 1: Age-related Macular Degeneration Moderators: S. Sadda, D. Sarraf, K. Bailey Freund, E. Souied 09.00-09.15 Prospective SD OCT Analysis of PED Associated with
More informationTrends in Ophthalmology a Market Perspective. Matthias Karl, Michael Kempe
Trends in Ophthalmology a Market Perspective Matthias Karl, Michael Kempe 30.04.2013 Agenda 1 2 3 4 Role of Optical Technologies in Ophthalmology Demands of the Market - Trends in the Application Implications
More informationICG IMAGING FOR EXUDATIVE ARMD
ICG IMAGING FOR EXUDATIVE ARMD MARK H. NELSON, MD MBA WINSTON-SALEM, NC ASRS INSTRUCTION COURSE AUGUST 24, 2011 FINANCIAL DISCLOSURE Novartis Pharmaceutics, Incorporated Consultant, Grant Recipient Heidelberg
More informationMedikamentöse Behandlung des Makulaödems. 1. NSAID 2. Steroide 3. Karboanhydrase-Hemmer 4. Anti-VEGF
Medikamentöse Behandlung des Makulaödems 1. NSAID 2. Steroide 3. Karboanhydrase-Hemmer 4. Anti-VEGF Pharmakotherapie des Makulaödems Wirkungsorte Innere BRS Äussere BRS NSAIDs Steroide NSAIDs Steroide
More informationAdvocating for Improved Treatment and Outcomes for Diabetic Macular Edema
Advocating for Improved Treatment and Outcomes for Diabetic Macular Edema A Report Based on an International Expert Summit Convened in Paris, June 2014 Acknowledgements This publication was supported by
More informationCharles C Wykoff, David M Brown, Maria E Maldonado, Daniel E Croft. Clinical science
Aflibercept treatment for patients with exudative age-related macular degeneration who were incomplete responders to multiple ranibizumab injections (TURF trial) Charles C Wykoff, David M Brown, Maria
More informationLong-term Outcomes of Ranibizumab Therapy for Diabetic Macular Edema: The 36-Month Results from Two Phase III Trials
Long-term Outcomes of Therapy for Diabetic Macular Edema: The 36-Month Results from Two Phase III Trials RISE and RIDE David M. Brown, MD, 1,x Quan Dong Nguyen, MD, MSc, 2,x Dennis M. Marcus, MD, 3 David
More informationSpectral domain OCT used to view and quantify choroidal vascular congestion in new subretinal fluid following scleral buckling.
Spectral domain OCT used to view and quantify choroidal vascular congestion in new subretinal fluid following scleral buckling. Robert Gizicki MD, Mohamed Haji, Flavio Rezende Retina Service, Hôpital Maisonneuve-Rosemont,
More informationWhich eye conditions can avastin injections be used for?
What is avastin? Avastin is a drug that is licensed for the treatment of a certain type of colorectal cancer but can also be used to treat certain eye conditions by being injected into the eye. Although
More information1981-1982 Ophthalmic Consultants Northwest, Seattle, Washington Retinal and vitreous consultation and surgery
EDUCATION Richard S. Munsen Jr., MD University of Washington Eye Institute HMC Box 359608, 325 Ninth Ave, Seattle WA 98104-2499 (206) 744-2020 for patient appointments, Fax (206) 897-4320 Academic phone
More informationPERIOCULAR (SUBTENON) STEROID INJECTION ERIC S. MANN M.D.,Ph.D.
PERIOCULAR (SUBTENON) STEROID INJECTION ERIC S. MANN M.D.,Ph.D. A. INDICATIONS: Periocular steroid injection involves placement of steroid around the eye to treat intraocular inflammation or swelling of
More informationThe Long-term Effects of Laser Photocoagulation Treatment in Patients with Diabetic Retinopathy
The Long-term Effects of Laser Photocoagulation Treatment in Patients with Diabetic Retinopathy The Early Treatment Diabetic Retinopathy Follow-up Study Emily Y. Chew, MD, 1 Frederick L. Ferris III, MD,
More informationGlaucoma. OET: Reading Part A. Reading Sub-test. Complete the following summary using the information in the four texts provided.
Glaucoma Reading Sub-test TIME LIMIT: 15 MINUTES Complete the following summary using the information in the four texts provided. You do not need to read each text from beginning to end to complete the
More informationIntroduction Houston Retina Associates
1 2 Introduction This book was written by Houston Retina Associates to provide our patients with basic knowledge about retinal anatomy, an introduction to some of the diagnostic tests and treatments used
More informationA Focus on Clinical Research
SUPPLEMENT TO NOVEMBER 2014 www.reviewofoptometry.com A Focus on Clinical Research This year, our experts review and summarize the landmark trials that most directly influenced the course of retinal disease
More informationOptic Disc Drusen. Normal Enlarged view of Optic Disc. Lumpy Appearance of Optic Disc. Optic Disc Drusen With Drusen
Optic Disc Drusen Your doctor has diagnosed you with optic disc drusen. Optic disc drusen are abnormal deposits of protein-like material in the optic disc the front part of the optic nerve. We do not know
More informationVitreo-Retinal and Macular Degeneration Frequently Asked Questions
Vitreo-Retinal and Macular Degeneration Frequently Asked Questions What is a Vitreo-Retinal specialist? Retinal specialists are eye physicians and surgeons who focus on diseases in the back of the eye
More informationon behalf of the AUGMENT-HF Investigators
One Year Follow-Up Results from AUGMENT-HF: A Multicenter Randomized Controlled Clinical Trial of the Efficacy of Left Ventricular Augmentation with Algisyl-LVR in the Treatment of Heart Failure* Douglas
More informationLaser Treatment for Proliferative Diabetic Retinopathy (PDR) Pan Retinal Photocoagulation (PRP)
Laser Treatment for Proliferative Diabetic Retinopathy (PDR) Pan Retinal Photocoagulation (PRP) Ophthalmology Department Page 12 Patient Information Further Information We endeavour to provide an excellent
More informationAngiogenesis, Exudation, and Degeneration 2015. February 7, 2015 Mandarin Oriental, Miami, Florida
Angiogenesis, Exudation, and Degeneration 2015 February 7, 2015 Mandarin Oriental, Miami, Florida Program Directors: Philip J. Rosenfeld, MD, PhD and Harry W. Flynn, Jr., MD Course Associate Director:
More informationMeasure of Confidence. Glaucoma Module Premium Edition
Measure of Confidence Glaucoma Module Premium Edition The Changing Face of Glaucoma Practice Literature 1 Leske et al., Arch Ophthalmol 1997; 115:1051-1057 2 Doughty et al., Surv Ophthalmol 2000; 44:367-408
More informationKomorbide brystkræftpatienter kan de tåle behandling? Et registerstudie baseret på Danish Breast Cancer Cooperative Group
Komorbide brystkræftpatienter kan de tåle behandling? Et registerstudie baseret på Danish Breast Cancer Cooperative Group Lotte Holm Land MD, ph.d. Onkologisk Afd. R. OUH Kræft og komorbiditet - alle skal
More informationRetina InSight Volume 1 Issue 1 Fall 2014
Retina InSight Volume 1 Issue 1 Fall 2014 Welcome to our GHRRF Newsletter! We are passionate about fighting blindness through cutting edge research. The purpose of this newsletter is to share information
More informationAngiogenesis, Exudation, and Degeneration 2014. February 8, 2014 Mandarin Oriental, Miami, Florida
Angiogenesis, Exudation, and Degeneration 2014 February 8, 2014 Mandarin Oriental, Miami, Florida Program Directors: Philip J. Rosenfeld, MD, PhD and Harry W. Flynn, Jr., MD Course Associate Director:
More informationRobert Okwemba, BSPHS, Pharm.D. 2015 Philadelphia College of Pharmacy
Robert Okwemba, BSPHS, Pharm.D. 2015 Philadelphia College of Pharmacy Judith Long, MD,RWJCS Perelman School of Medicine Philadelphia Veteran Affairs Medical Center Background Objective Overview Methods
More informationDIABETIC RETINOPATHY
DIABETIC RETINOPATHY Dr. Ajay I. Dudani M.S. (Bom.) D.N.B. (Ophth) F.C.P.S., D.O.M.S. (Bom.) angiography, microaneurysms f requently leak dye, implying a focal breakdown in the blood-retinal barrier. Capillary
More informationU.S. Food and Drug Administration
U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDA s website for reference purposes only. It was current when produced, but is no longer maintained
More informationPATIENT INFORMATION BOOKLET
(060110) VISIONCARE S IMPLANTABLE MINIATURE TELESCOPE ( BY DR. ISAAC LIPSHITZ ) AN INTRAOCULAR TELESCOPE FOR TREATING SEVERE TO PROFOUND VISION IMPAIRMENT DUE TO BILATERAL END-STAGE AGE-RELATED MACULAR
More informationLaser Procedure Note
Laser Procedure Note Patient Name Date 1. Pre procedure diagnosis 2. Procedure and Eye Eye: 3. Pre procedure topical medications administered (and time) 4. Vital signs BP / HR Acuity OD: OS: 5. IOP: OD
More informationNATIONAL CANCER DRUG FUND PRIORITISATION SCORES
NATIONAL CANCER DRUG FUND PRIORITISATION SCORES Drug Indication Regimen (where appropriate) BORTEZOMIB In combination with dexamethasone (VD), or with dexamethasone and thalidomide (VTD), is indicated
More informationEffect of retinal laser photocoagulation on contrast sensitivity and visual acuity in patients of diabetic retinopathy
International Journal of Scientific and Research Publications, Volume 4, Issue 10, October 2014 1 Effect of retinal laser photocoagulation on contrast sensitivity and visual acuity in patients of diabetic
More informationSystolic Blood Pressure Intervention Trial (SPRINT) Principal Results
Systolic Blood Pressure Intervention Trial (SPRINT) Principal Results Paul K. Whelton, MB, MD, MSc Chair, SPRINT Steering Committee Tulane University School of Public Health and Tropical Medicine, and
More information6/5/2014. Objectives. Acute Coronary Syndromes. Epidemiology. Epidemiology. Epidemiology and Health Care Impact Pathophysiology
Objectives Acute Coronary Syndromes Epidemiology and Health Care Impact Pathophysiology Unstable Angina NSTEMI STEMI Clinical Clues Pre-hospital Spokane County EMS Epidemiology About 600,000 people die
More informationAvastin (Renal Cell Carcinoma) - Analysis and Forecasts to 2022
Brochure More information from http://www.researchandmarkets.com/reports/2228475/ Avastin (Renal Cell Carcinoma) - Analysis and Forecasts to 2022 Description: Avastin (Renal Cell Carcinoma) Analysis and
More informationwww.retinatoday.com ULTIMATE TECHNICIAN S SURVIVAL GUIDE 2014-2015 eyetube.net
www.retinatoday.com ULTIMATE TECHNICIAN S SURVIVAL GUIDE 2014-2015 eyetube.net Providing Assistance in Support of Patients Helps eligible patients* with commercial insurance cover certain out-of-pocket
More informationRenovascular Hypertension
Renovascular Hypertension Philip Stockwell, MD Assistant Professor of Medicine (Clinical) Warren Alpert School of Medicine Cardiology for the Primary Care Provider September 28, 201 Renovascular Hypertension
More informationPressure Ulcers in the ICU Incidence, Risk Factors & Prevention
Congress of the Critical Care Society of South Africa Sun City, 10-12 July 2015 Pressure Ulcers in the ICU Incidence, Risk Factors & Prevention Stijn BLOT Dept. of Internal Medicine Faculty of Medicine
More informationSECONDARY GLAUCOMA: Pseudoexfoliation (PXF), Pigmentary Dispersion Syndrome (PDS), Neovascular (NV), Uveitic
SECONDARY GLAUCOMA: Pseudoexfoliation (PXF), Pigmentary Dispersion Syndrome (PDS), Neovascular (NV), Uveitic Many roads can lead to glaucoma. With the exception of primary open-angle glaucoma (POAG) and
More informationNeovascular glaucoma is a serious complication of systemic
GLAUCOMA SURGERY Robert F. Haverly, MD, FACS Abstract: Neovascular glaucoma is a vision- and eye-threatening disease that carries a poor prognosis. Understanding the cause of neovascular glaucoma with
More informationDOSAGE FORMS AND STRENGTHS Intravitreal implant containing dexamethasone 0.7 mg in the NOVADUR solid polymer drug delivery system.
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use OZURDEX safely and effectively. See full prescribing information for OZURDEX. OZURDEX (dexamethasone
More informationDiabetic Eye Screening Revised Grading Definitions
Diabetic Eye Screening Revised Grading Definitions Version 1.3, 1 November 2012 To provide guidance on revised grading definitions for the NHS Diabetic Eye Screening Programme Project/Category Document
More informationRetina InSight Volume 2 Winter 2015/2016
Retina InSight Volume 2 Winter 2015/2016 News from the Greater Houston Retina Research Foundation RCH Retina Rangers Give Back at Houston VisionWalk 2015 Hearts were pounding and pulses racing at the 2015
More informationBasic of Epidemiology in Ophthalmology Rajiv Khandekar. Presented in the 2nd Series of the MEACO Live Scientific Lectures 11 August 2014 Riyadh, KSA
Basic of Epidemiology in Ophthalmology Rajiv Khandekar Presented in the 2nd Series of the MEACO Live Scientific Lectures 11 August 2014 Riyadh, KSA Basics of Epidemiology in Ophthalmology Dr Rajiv Khandekar
More informationEye Diseases. 1995-2014, The Patient Education Institute, Inc. www.x-plain.com otf30101 Last reviewed: 05/21/2014 1
Eye Diseases Introduction Some eye problems are minor and fleeting. But some lead to a permanent loss of vision. There are many diseases that can affect the eyes. The symptoms of eye diseases vary widely,
More informationAtherosclerosis of the aorta. Artur Evangelista
Atherosclerosis of the aorta Artur Evangelista Atherosclerosis of the aorta Diagnosis Classification Prevalence Risk factors Marker of generalized atherosclerosis Risk of embolism Therapy Diagnosis Atherosclerosis
More informationCommissioning better eye care
Commissioning better eye care Clinical commissioning guidance from The College of Optometrists and The Royal College of Ophthalmologists Age-related macular degeneration Version: 1 Published: 25 Nov 2013
More information2015 Half Year Results Conference Call Presentation. 26 August 2015
2015 Half Year Results Conference Call Presentation 26 August 2015 1 Today s Call Participants Dr Patrik De Haes - CEO Dominique Vanfleteren CFO 2 Agenda for the Call 2015 Highlights US update : objectives
More informationTucson Eye Care, PC. Informed Consent for Cataract Surgery And/Or Implantation of an Intraocular Lens
Tucson Eye Care, PC Informed Consent for Cataract Surgery And/Or Implantation of an Intraocular Lens INTRODUCTION This information is provided so that you may make an informed decision about having eye
More information2016 International Stroke Conference Hot Topics Lori M. Massaro, MSN, CRNP Kari Moore, MSN, AGACNP-BC
2016 International Stroke Conference Hot Topics Lori M. Massaro, MSN, CRNP Kari Moore, MSN, AGACNP-BC Disclosures Lori M. Massaro, MSN,CRNP speakers bureau Genentech Kari Moore, MSN, AGACNP-BC -none 1
More information2013 Diabetes and Eye Disease Fact Sheet
The Georgia Department of Public Health 2013 Diabetes and Eye Disease Fact Sheet Diabetes is the leading cause of new cases of blindness among United States adults. 1-3 As Georgia s population ages and
More informationJNC-8 Blood Pressure and ACC/AHA Cholesterol Guideline Updates. January 30, 2014
JNC-8 Blood Pressure and ACC/AHA Cholesterol Guideline Updates January 30, 2014 GOALS Review key recommendations from recently published guidelines on blood pressure and cholesterol management Discuss
More information1/7/2012. Objectives. Epidemiology of Atrial Fibrillation(AF) Stroke in AF. Stroke Risk Stratification in AF
Objectives Atrial Fibrillation and Prevention of Thrombotic Complications: Therapeutic Update Andrea C. Flores Pharm.D Pharmacy Resident at the Miami VA Healthcare System Review the epidemiology, pathophysiology
More informationEXPANDING YOUR HORIZONS
Glaucoma Therapy EXPANDING YOUR HORIZONS Learn how to control glaucoma with SLT therapy. SLTPATIENT EDUCATION PROGRAM Glaucoma Glaucoma is a degenerative disease that if left untreated can cause permanent
More informationOUT OF SIGHT A REPORT INTO DIABETIC EYE DISEASE IN AUSTRALIA OUT OF SIGHT A REPORT INTO DIABETIC EYE DISEASE IN AUSTRALIA
1 OUT OF SIGHT A REPORT INTO DIABETIC EYE DISEASE IN AUSTRALIA 2 Authored by Dr Mohamed Dirani - Evaluative Research and Health Services Unit (CERA). Edited by Associate Professor Jonathan Shaw Associate
More informationVitreomacular Traction: What s the Role of the Vitreoretinal Interface in this Disease?
Vitreomacular Traction: What s the Role of the Vitreoretinal Interface in this Disease? Robert A. Stoltz, M.D., Ph.D. Georgia Retina, P.C. Retinal Pearls 2013 Anatomy of the Vitreous Gel Physical Properties
More informationTHOMAS IRA MARGOLIS, M. D. OFFICE ADDRESS: BIRTH DATE: May 11, 1962 1500 Tilton Road PROFESSIONAL EXPERIENCE
THOMAS IRA MARGOLIS, M. D. OFFICE ADDRESS: BIRTH DATE: May 11, 1962 1500 Tilton Road Northfield, NJ 08225 PLACE OF BIRTH: Uniontown, PA 609-646-5200 FAX 609-646-9868 PROFESSIONAL EXPERIENCE RETINAL AND
More informationEye Department Baden-Baden. Prof. Dr. med. Frank Faude Dr. med. Susanne Faude Oxana Bräunlich. Ophthalmology specialists
E y e D e p a r t m e n t Prof. Dr. med. Frank Faude Dr. med. Susanne Faude Oxana Bräunlich Ophthalmology specialists Prof. Dr. med. Frank Faude Inpatient and outpatient treatment at the Stadtklinik Baden-Baden
More informationIMAGE ASSISTANT: OPHTHALMOLOGY
IMAGE ASSISTANT: OPHTHALMOLOGY Summary: The Image Assistant has been developed to provide medical doctors with a software tool to search, display, edit and use medical illustrations of their own specialty,
More informationGeographic Atrophy: The Advanced Form of Dry AMD
Age-related macular degeneration (AMD) is a disease associated with aging that gradually destroys sharp, central vision. Central vision is needed for seeing objects clearly and for common daily tasks such
More informationObjectives. Preoperative Cardiac Risk Stratification for Noncardiac Surgery. History
Preoperative Cardiac Risk Stratification for Noncardiac Surgery Kimberly Boddicker, MD FACC Essentia Health Heart and Vascular Center 27 th Heart and Vascular Conference May 13, 2011 Objectives Summarize
More informationNEW HOPE AND CURE FOR GLAUCOMA TREATMENT Although the tools for glaucoma care have become more sophisticated and advanced over the past two decades,
NEW HOPE AND CURE FOR GLAUCOMA TREATMENT Although the tools for glaucoma care have become more sophisticated and advanced over the past two decades, the goal of cure is still beyond our reach, despite
More informationDrug/Drug Combination: Bevacizumab in combination with chemotherapy
AHFS Final Determination of Medical Acceptance: Off-label Use of Bevacizumab in Combination with Chemotherapy for the Treatment of Metastatic Breast Cancer Previously Treated with Cytotoxic Chemotherapy
More informationitems or information listed below and bring to your first visit:
ALAN L. WAGNER, M.D. F.A.C.S. DISEASES & SURGERY OF RETINA & VITREOUS MACULAR DEGENERATION DIABETIC RETINOPATHY RETINAL DETACHMENT ADULT & PEDIATRIC RETINAL SURGERY OCULAR ONCOLOGY / BRACHYTHERAPY INDOCYANINE
More informationRetinal Imaging Biomarkers for Early Diagnosis of Alzheimer s Disease
Retinal Imaging Biomarkers for Early Diagnosis of Alzheimer s Disease Eleonora (Nora) Lad, MD, PhD Assistant Professor of Ophthalmology, Vitreoretinal diseases Duke Center for Macular Diseases Duke University
More informationCRYOTHERAPY FOR RETINAL BREAK, LATTICE DEGENERATION, OR LIMITED RETINAL DETACHMENT ERIC S. MANN M.D., Ph.D.
CRYOTHERAPY FOR RETINAL BREAK, LATTICE DEGENERATION, OR LIMITED RETINAL DETACHMENT ERIC S. MANN M.D., Ph.D. A. INTRODUCTION: Retinal break is an opening on the retina, usually located at the periphery.
More informationRetinal Detachments Mark E. Hammer, M.D. Ivan J. Suñer, M.D. Marc C. Peden, M.D.
Retinal Detachments Mark E. Hammer, M.D. Ivan J. Suñer, M.D. Marc C. Peden, M.D. What is a retinal detatchment? The retina is the light sensitive layer covering the inside of the back of the eye. It is
More informationPatient Information Cataract surgery
Patient Information Cataract surgery Introduction This leaflet has been written to help you understand more about surgery for a cataract. It explains what the operation involves, the benefits and risks
More informationPreparing for laser treatment for diabetic retinopathy and maculopathy
Preparing for laser treatment for diabetic retinopathy and maculopathy This leaflet sets out to answer the questions people with diabetic retinopathy commonly ask about laser treatment. You might want
More information04/03/2015. EMR Documentation and Compliance: The Retina Point of View. Financial Disclosure. Financial Disclosure
EMR Documentation and Compliance: The Retina Point of View William T. Koch, COA, COE, CPC The Retina Institute Kirk A. Mack, COMT, COE, CPC, CPMA Corcoran Consulting Group Financial Disclosure William
More information2016 PQRS OPTIONS FOR INDIVIDUAL MEASURES: CLAIMS, REGISTRY
Measure #317: Preventive Care and Screening: Screening for High Blood Pressure and Follow-Up Documented National Quality Strategy Domain: Community / Population Health 2016 PQRS OPTIONS F INDIVIDUAL MEASURES:
More informationOphthalmic Innovation 2015 A View from the AAO
Ophthalmic Innovation 215 A View from the AAO Ophthalmic Innovation 215: a view from the AAO IRIS David W. Parke II, MD CEO American Academy of Ophthalmology Introduction to AAO s IRIS Registry IRIS Registry
More informationFacts about diabetic macular oedema
Patient information medical retina services Facts about diabetic macular oedema What is diabetic macular oedema? Diabetic eye disease is a leading cause of blindness registration among working age adults
More informationMATTHEW J. WELCH, M.D.
MATTHEW J. WELCH, M.D. PROFESSIONAL PRACTICE Retina Specialists of Southern Arizona Associated Retina Consultants Tucson Division 4753 E Camp Lowell Dr, Tucson, AZ 85712 Suburban Retina, Ltd. 2013 2014
More information~Contributing to Eye Health~
~Contributing to Eye Health~ 26 Eye Care Market Trends FY2007 Retinal Camera market forecasts by eye disease FY 2010 Auto Keratorefractometer Retina 160 Refraction Retina 200 Refraction Auto Lens Edger
More informationWhen a Macular Hole Is Not A Macular Hole. Contents. OCT Anatomy. Vitreomacular Traction 3/1/2012
When a Macular Hole Is Not A Macular Hole Salil Shukla, MD Omni Eye Specialists Spring Symposium March 3, 2012 Contents Vitreomacular Traction Epiretinal Membrane Lamellar Hole Macular Hole (Myopic macular
More informationCardiac Assessment for Renal Transplantation: Pre-Operative Clearance is Only the Tip of the Iceberg
Cardiac Assessment for Renal Transplantation: Pre-Operative Clearance is Only the Tip of the Iceberg 2 nd Annual Duke Renal Transplant Symposium March 1, 2014 Durham, NC Joseph G. Rogers, M.D. Associate
More informationThis clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.
abcd Clinical Study for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis which is part of the clinical
More information